Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV For The Treatment Of Chronic Hepatitis Delta Virus Infection And ALN-PDL For The Treatment Of Chronic Liver Infections
November 11, 2014 at 08:02 AM EST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic ...
